AACR 2025 Recap: Immunotherapy Shifts, ctDNA Surveillance, and Breakthroughs in HER2 and AML
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
AACR 2025 Recap: Immunotherapy Shifts, ctDNA Surveillance, and Breakthroughs in HER2 and AML
-
Narrated by:
-
By:
About this listen
In this post-conference episode, Mike breaks down five major stories from AACR 2025:
- KEYNOTE-689 trial changes the standard of care in head and neck cancer
- Zongertinib delivers HER2-targeted efficacy with fewer side effects in lung cancer
- CAR NK cells show durable remission in AML
- ctDNA testing in CRC detects recurrence 6+ months before imaging
- Werner helicase inhibitor shows first-in-class potential in MSI tumors
Listen in for a concise roundup of the data and why it matters.
activate_mytile_page_redirect_t1
What listeners say about AACR 2025 Recap: Immunotherapy Shifts, ctDNA Surveillance, and Breakthroughs in HER2 and AML
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.